Last reviewed · How we verify
NCT06693440
The Immune Assessment of PD-1 Antibody Therapy in Tumor
trial testing PD-1 Inhibitors in Efficacy, Team in 3,000 participants. Currently enrolling.
13 November 2027
Quick facts
| Lead sponsor | Quanli Gao |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 3,000 |
| Start date | 1 July 2021 |
| Primary completion | 13 November 2027 |
| Estimated completion | 13 November 2030 |
| Sites | 1 location across China |
Drugs / interventions tested
- PD-1 Inhibitors — full drug profile →
Conditions studied
- Efficacy, Team — all drugs for Efficacy, Team →
- Adverse Event — all drugs for Adverse Event →
Sponsor
Quanli Gao
Who can join
18 and older, any sex, with Efficacy, Team or Adverse Event. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This retrospective study will leverage previous immune function monitoring results in conjunction with clinical case data at this medical center.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The baseline circulating immunophenotype characteristics associate with PD(L)-1 targeted treatment response, irae onset, and prognosis.
Fu X, Li F, You H, Xu B, et al · · 2025 · cited 2× · PMID 40394154 · DOI 10.1038/s41598-025-02597-5
Verify or expand the search:
- PubMed search for NCT06693440
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PD-1 Inhibitors
Trials testing the same drug.
- NCT07466225 — HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion · not yet recruiting
- NCT07379489 — Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma · not yet recruiting
- NCT07359040 — Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer · active not recruiting
- NCT07070479 — Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Tr · Phase 2 · recruiting
- NCT06740370 — TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma · NA · recruiting
Other Quanli Gao trials
Trials by the same sponsor.
- NCT05878028 — L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC · Phase 2 · recruiting
- NCT04924413 — L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma · Phase 2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06693440 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Quanli Gao
- Last refreshed: 18 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06693440.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing